-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria --

-- Late-breaking poster presentation on CDX-622 --

HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that three presentations from the barzolvolimab and CDX-622 programs will be shared at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress being held in Istanbul, Türkiye, on June 12-15, 2026.

Results supporting Celldex's leadership and barzolvolimab's first-in-class, best-in-disease profile in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) will be presented in two flash talks.

New, first-in-human results from the Phase 1 trial of the novel bispecific CDX-622 in healthy volunteers will be presented in a late-breaking poster session, highlighting the potential for bispecific targeting of soluble stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP) to inhibit KIT signaling in mast cells.